Landscape and time course of Comprehensive Genomic Profiling (CGP) Test Utilization in Cancer Patients in Japan

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030250365

Enrollment

97000

Registered

2025-09-17

Start date

2025-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients who had any records in the C-CAT registry from June 1, 2019 and August 23, 2025.

Exclusion criteria

Exclusion criteria: Patients who did not have data on either CGP test results or follow-up.

Design outcomes

Primary

Measure	Time frame
1. Patient characteristic and basic information: gender, age, cancer type, specimen information, smoking history, alcohol consumption, ECOG PS, cancer stage, age at onset, and history of drug treatment 2. Drug treatment after CGP tests: EP presented new therapeutic drug options, and dministered the presented therapeutic agent 3. Outcome: death, date of death, and CGP test result	—

Contacts

Public ContactMasashi Mikami

Pfizer Japan Inc.

kanae.togo@pfizer.com+81-3-5309-7000

Outcome results